CombiGene´s lead project CG01 has received funding from the European Union´s Horizon 2020 research and innovation programme

Study with brain tissue from human epilepsy patients confirms that brain cells express CombiGene’s candidate drug CG01

Dec 14, 2017

CombiGene has, in collaboration with Associate Professor David Woldbye at University of Copenhagen and Professor Merab Kokaia at Lund University, carried out a so-called ”human expression study”, i.e. a study using brain tissue from human epilepsy patients. A similar study with positive results has previously been carried out when neuropeptide Y was directly applied to human tissue of the same kind. Neuropeptide Y is the neurotransmitter that CG01 expresses in the brain via genes. This is, however, the first study testing the candidate drug, CG01, in human tissue.